UK Government Faces Pressure on Pelvic Mesh, Valproate Payouts

The UK government is facing renewed pressure to establish compensation for individuals harmed by pelvic mesh and the epilepsy drug sodium valproate. Professor Henrietta Hughes, England's patient safety commissioner, voiced disappointment regarding the lack of visible progress on redress schemes recommended over two years ago. These schemes aim to address avoidable harm suffered by patients. Transvaginal mesh implants, used between 1998 and 2020 for pelvic organ prolapse and incontinence, have caused severe injuries, sometimes necessitating organ removal. The NHS now uses them only as a last resort.

Thousands of babies may have been harmed by sodium valproate use during pregnancies since the 1970s. This drug, prescribed for epilepsy and bipolar disorder, is known to cause birth defects and lifelong learning difficulties, impacting an estimated 20,000 families. Professor Hughes's report suggested interim compensation payments of £25,000 for victims, with payments potentially starting in 2025. However, she notes the government has not yet provided a substantive response to these urgent recommendations.